Rigel Pharmaceuticals (RIGL) CFO reports multiple option exercises and share ownership

Rhea-AI Filing Summary

Rigel Pharmaceuticals' EVP & Chief Financial Officer reported option exercises and updated holdings. On 12/22/2025, the officer exercised three employee stock options (code M), acquiring 1,987 shares at $20, 2,846 shares at $24.2, and 1,667 shares at $18.7 per share.

Following these transactions, the officer beneficially owned 64,235 shares of Rigel common stock, which includes 500 shares acquired under the company’s stock purchase plan. The filing also shows remaining employee stock options covering 14,262, 17,153, and 10,832 shares, with expiration dates ranging from 01/23/2029 to 01/26/2033. All share numbers reflect a one-for-ten reverse stock split effective June 27, 2024, and the options vest in equal monthly installments over four years from their respective vesting commencement dates.

Insider Trade Summary

6,500 shares exercised/converted

Mixed 6 txns

Insider Schorno Dean L

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	1,987	$0.00	--
Exercise	Employee Stock Option (right to buy)	2,846	$0.00	--
Exercise	Employee Stock Option (right to buy)	1,667	$0.00	--
Exercise	Common Stock	1,987	$20.00	$40K
Exercise	Common Stock	2,846	$24.20	$69K
Exercise	Common Stock	1,667	$18.70	$31K

Holdings After Transaction: Employee Stock Option (right to buy) — 14,262 shares (Direct); Common Stock — 59,722 shares (Direct)

Footnotes (1)

1. These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Includes 500 shares of common stock acquired under the Issuer's stock purchase plan. The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019, subject to the reporting person's continuous service to the Issuer through each such period. The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the Issuer through each such period. The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schorno Dean L

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/22/2025		M		1,987(1)	A	$20(1)	59,722(2)	D
Common Stock	12/22/2025		M		2,846(1)	A	$24.2(1)	62,568	D
Common Stock	12/22/2025		M		1,667(1)	A	$18.7(1)	64,235	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$20(1)	12/22/2025		M			1,987(1)	(3)	01/23/2029	Common Stock	1,987(1)	$0	14,262(1)	D
Employee Stock Option (right to buy)	$24.2(1)	12/22/2025		M			2,846(1)	(4)	02/06/2030	Common Stock	2,846(1)	$0	17,153(1)	D
Employee Stock Option (right to buy)	$18.7(1)	12/22/2025		M			1,667(1)	(5)	01/26/2033	Common Stock	1,667(1)	$0	10,832(1)	D

Explanation of Responses:

1. These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

2. Includes 500 shares of common stock acquired under the Issuer's stock purchase plan.

3. The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019, subject to the reporting person's continuous service to the Issuer through each such period.

4. The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the Issuer through each such period.

5. The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.

	/s/ Raymond Furey (Attorney-in-Fact)	12/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RIGL’s CFO report on this Form 4?

The EVP & Chief Financial Officer of Rigel Pharmaceuticals, Inc. (RIGL) reported exercising three employee stock options on 12/22/2025, acquiring 1,987, 2,846, and 1,667 shares of common stock at exercise prices of $20, $24.2, and $18.7 per share, respectively.

How many Rigel (RIGL) shares does the reporting person own after these transactions?

After the reported option exercises, the officer beneficially owned 64,235 shares of Rigel Pharmaceuticals common stock, including 500 shares acquired under the issuer’s stock purchase plan.

What types of securities were involved in this RIGL Form 4 filing?

The filing covers common stock and employee stock options (right to buy) that were exercised on 12/22/2025, converting options into shares of Rigel Pharmaceuticals common stock.

What employee stock options does the RIGL officer still hold after the exercises?

Following the transactions, the officer held employee stock options over 14,262 shares at an exercise price of $20, 17,153 shares at $24.2, and 10,832 shares at $18.7, with expiration dates of 01/23/2029, 02/06/2030, and 01/26/2033, respectively.

How did Rigel’s reverse stock split affect the share numbers in this Form 4?

All share figures in the filing, including option and common stock amounts, have been adjusted to reflect a one-for-ten reverse stock split that was effective on June 27, 2024.

What is the reporting person’s role and relationship to Rigel Pharmaceuticals (RIGL)?

The reporting person is an officer of Rigel Pharmaceuticals, serving as EVP & Chief Financial Officer, and the Form 4 is filed for one reporting person, not a group.